News

Kauppalehti1d
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.
Agence France-Presse5d
ASCO 2025: REVEAL GENOMICS Unveils New HER2DX Data From 800+ Patients
REVEAL GENOMICS, S.L., a biotechnology company advancing precision oncology through biomarker innovation, today announced the ...
finanzen.at1d
Press Release: Novartis Kisqali(R) reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
Novartis is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety of Kisqali(R) (ribociclib) plus endocrine therapy (ET, a non-steroidal ...
EuropaWire1h
Novartis Presents ASCO Data Showing Kisqali’s Efficacy and Tolerability in High-Risk Early Breast Cancer Patients
Novartis has presented new data from the Phase III NATALEE trial at ASCO 2025, showcasing Kisqali’s ability to reduce the risk of recurrence in ...
Health And Pharma5d
Improving Everolimus Safety in Oncology: Missed Opportunities in Risk Minimization
Despite two decades of clinical experience with Everolimus in transplant medicine, cancer patients continue to face ...